206 related articles for article (PubMed ID: 33449689)
1. Design and Evaluation of Peptide Dual-Agonists of GLP-1 and NPY2 Receptors for Glucoregulation and Weight Loss with Mitigated Nausea and Emesis.
Milliken BT; Elfers C; Chepurny OG; Chichura KS; Sweet IR; Borner T; Hayes MR; De Jonghe BC; Holz GG; Roth CL; Doyle RP
J Med Chem; 2021 Jan; 64(2):1127-1138. PubMed ID: 33449689
[TBL] [Abstract][Full Text] [Related]
2. A novel dual agonist of glucagon-like peptide-1 receptors and neuropeptide Y2 receptors attenuates fentanyl taking and seeking in male rats.
Zhang Y; Rahematpura S; Ragnini KH; Moreno A; Stecyk KS; Kahng MW; Milliken BT; Hayes MR; Doyle RP; Schmidt HD
Neuropharmacology; 2021 Jul; 192():108599. PubMed ID: 33965397
[TBL] [Abstract][Full Text] [Related]
3. Reductions of food intake and body weight in diet-induced obese rats following chronic treatment with a monomeric peptide multiagonist.
Elfers CT; Chichura KS; Ashlaw EF; Chepurny OG; Holz GG; Doyle RP; Roth CL
Clin Nutr; 2024 Jul; 43(7):1782-1790. PubMed ID: 38861891
[TBL] [Abstract][Full Text] [Related]
4. GIP Receptor Agonism Attenuates GLP-1 Receptor Agonist-Induced Nausea and Emesis in Preclinical Models.
Borner T; Geisler CE; Fortin SM; Cosgrove R; Alsina-Fernandez J; Dogra M; Doebley S; Sanchez-Navarro MJ; Leon RM; Gaisinsky J; White A; Bamezai A; Ghidewon MY; Grill HJ; Crist RC; Reiner BC; Ai M; Samms RJ; De Jonghe BC; Hayes MR
Diabetes; 2021 Nov; 70(11):2545-2553. PubMed ID: 34380697
[TBL] [Abstract][Full Text] [Related]
5. A peptide triple agonist of GLP-1, neuropeptide Y1, and neuropeptide Y2 receptors promotes glycemic control and weight loss.
Chichura KS; Elfers CT; Salameh TS; Kamat V; Chepurny OG; McGivney A; Milliken BT; Holz GG; Applebey SV; Hayes MR; Sweet IR; Roth CL; Doyle RP
Sci Rep; 2023 Jun; 13(1):9554. PubMed ID: 37308546
[TBL] [Abstract][Full Text] [Related]
6. Synthesis, Optimization, and Biological Evaluation of Corrinated Conjugates of the GLP-1R Agonist Exendin-4.
Tinsley IC; Borner T; Swanson ML; Chepurny OG; Doebley SA; Kamat V; Sweet IR; Holz GG; Hayes MR; De Jonghe BC; Doyle RP
J Med Chem; 2021 Mar; 64(6):3479-3492. PubMed ID: 33677970
[TBL] [Abstract][Full Text] [Related]
7. A second-generation glucagon-like peptide-1 receptor agonist mitigates vomiting and anorexia while retaining glucoregulatory potency in lean diabetic and emetic mammalian models.
Borner T; Shaulson ED; Tinsley IC; Stein LM; Horn CC; Hayes MR; Doyle RP; De Jonghe BC
Diabetes Obes Metab; 2020 Oct; 22(10):1729-1741. PubMed ID: 32410372
[TBL] [Abstract][Full Text] [Related]
8. Glucagon-like peptide-1 in diabetes care: Can glycaemic control be achieved without nausea and vomiting?
Borner T; Tinsley IC; Doyle RP; Hayes MR; De Jonghe BC
Br J Pharmacol; 2022 Feb; 179(4):542-556. PubMed ID: 34363224
[TBL] [Abstract][Full Text] [Related]
9. GLP-1 receptors are involved in the GLP-1 (7-36) amide-induced modulation of glucose homoeostasis, emesis and feeding in Suncus murinus (house musk shrew).
Lu Z; Chan SW; Tu L; Ngan MP; Rudd JA
Eur J Pharmacol; 2020 Dec; 888():173528. PubMed ID: 32871177
[TBL] [Abstract][Full Text] [Related]
10. Potentiation of insulin secretion and improvement of glucose intolerance by combining a novel G protein-coupled receptor 40 agonist DS-1558 with glucagon-like peptide-1 receptor agonists.
Nakashima R; Yano T; Ogawa J; Tanaka N; Toda N; Yoshida M; Takano R; Inoue M; Honda T; Kume S; Matsumoto K
Eur J Pharmacol; 2014 Aug; 737():194-201. PubMed ID: 24858371
[TBL] [Abstract][Full Text] [Related]
11. The Novel Chimeric Multi-Agonist Peptide (GEP44) Reduces Energy Intake and Body Weight in Male and Female Diet-Induced Obese Mice in a Glucagon-Like Peptide-1 Receptor-Dependent Manner.
Blevins JE; Honeycutt MK; Slattery JD; Goldberg M; Rambousek JR; Tsui E; Dodson AD; Shelton KA; Salemeh TS; Elfers CT; Chichura KS; Ashlaw EF; Zraika S; Doyle RP; Roth CL
bioRxiv; 2024 May; ():. PubMed ID: 38826286
[TBL] [Abstract][Full Text] [Related]
12. Novel small molecule glucagon-like peptide-1 receptor agonist stimulates insulin secretion in rodents and from human islets.
Sloop KW; Willard FS; Brenner MB; Ficorilli J; Valasek K; Showalter AD; Farb TB; Cao JX; Cox AL; Michael MD; Gutierrez Sanfeliciano SM; Tebbe MJ; Coghlan MJ
Diabetes; 2010 Dec; 59(12):3099-107. PubMed ID: 20823098
[TBL] [Abstract][Full Text] [Related]
13. Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates.
Henderson SJ; Konkar A; Hornigold DC; Trevaskis JL; Jackson R; Fritsch Fredin M; Jansson-Löfmark R; Naylor J; Rossi A; Bednarek MA; Bhagroo N; Salari H; Will S; Oldham S; Hansen G; Feigh M; Klein T; Grimsby J; Maguire S; Jermutus L; Rondinone CM; Coghlan MP
Diabetes Obes Metab; 2016 Dec; 18(12):1176-1190. PubMed ID: 27377054
[TBL] [Abstract][Full Text] [Related]
14. Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro.
Parkes DG; Pittner R; Jodka C; Smith P; Young A
Metabolism; 2001 May; 50(5):583-9. PubMed ID: 11319721
[TBL] [Abstract][Full Text] [Related]
15. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials.
Vilsbøll T; Christensen M; Junker AE; Knop FK; Gluud LL
BMJ; 2012 Jan; 344():d7771. PubMed ID: 22236411
[TBL] [Abstract][Full Text] [Related]
16. The role of nausea in food intake and body weight suppression by peripheral GLP-1 receptor agonists, exendin-4 and liraglutide.
Kanoski SE; Rupprecht LE; Fortin SM; De Jonghe BC; Hayes MR
Neuropharmacology; 2012 Apr; 62(5-6):1916-27. PubMed ID: 22227019
[TBL] [Abstract][Full Text] [Related]
17. Rapid selection of a novel GLP-1/GIP dual receptor agonist with prolonged glycemic control and weight loss in rodent animals.
Wu Y; Ji T; Lv J; Wang Z
Life Sci; 2020 Sep; 257():118025. PubMed ID: 32598933
[TBL] [Abstract][Full Text] [Related]
18. A novel approach to treating opioid use disorders: Dual agonists of glucagon-like peptide-1 receptors and neuropeptide Y
Merkel R; Moreno A; Zhang Y; Herman R; Ben Nathan J; Zeb S; Rahematpura S; Stecyk K; Milliken BT; Hayes MR; Doyle RP; Schmidt HD
Neurosci Biobehav Rev; 2021 Dec; 131():1169-1179. PubMed ID: 34715149
[TBL] [Abstract][Full Text] [Related]
19. Design of Novel Exendin-Based Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists.
Evers A; Haack T; Lorenz M; Bossart M; Elvert R; Henkel B; Stengelin S; Kurz M; Glien M; Dudda A; Lorenz K; Kadereit D; Wagner M
J Med Chem; 2017 May; 60(10):4293-4303. PubMed ID: 28448133
[TBL] [Abstract][Full Text] [Related]
20. Comparative effects of the long-acting GLP-1 receptor ligands, liraglutide and exendin-4, on food intake and body weight suppression in rats.
Hayes MR; Kanoski SE; Alhadeff AL; Grill HJ
Obesity (Silver Spring); 2011 Jul; 19(7):1342-9. PubMed ID: 21415845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
